Advanced Viral Research Corp. Initiates a Phase I, Safety Study for AVR118 in Type 2 Diabetic Subjects
Monday October 3, 7:03 am ET
YONKERS, N.Y.--(BUSINESS WIRE)--Oct. 3, 2005--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) announced today that it has initiated a Phase I, Double Blind, Placebo Controlled, Randomized, Single Center, Safety Study with AVR118 in Type 2 Diabetic Subjects in the U.S. Approximately 30 patients are expected to be entered in the study.The primary objective of this study is to explore the effect of 4.0 ml AVR118 given subcutaneously on blood glucose in subjects with type 2 diabetes who are on sulfonylureas and/or metformin, as compared to subjects not receiving AVR118. Sulfonylureas and metformin are commonly used drugs to control type 2 diabetes.
Additional objectives of this study are to explore the mechanism of action of AVR118 in potentially decreasing blood glucose in patients with type 2 diabetes and to explore the effect, if any, of AVR118 on other blood parameters associated with type 2 diabetes.
Currently, patients with diabetes are excluded from ADVR's studies. This Phase 1 study is designed to demonstrate whether there is any effect of AVR118 on glucose levels of patients with type 2 diabetes.
biz.yahoo.com |
